168 related articles for article (PubMed ID: 15023422)
1. The role of antifungal susceptibility testing in the therapy of candidiasis.
Hospenthal DR; Murray CK; Rinaldi MG
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):153-60. PubMed ID: 15023422
[TBL] [Abstract][Full Text] [Related]
2. [Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004].
Eloy O; Blanc V; Pina P; Gaudart A; Bressolle ML; Plainvert C; Decousser JW; Pangon B; Allouch PY;
Pathol Biol (Paris); 2006; 54(8-9):523-30. PubMed ID: 17029814
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
4. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
5. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
6. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
[TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
9. [The comparison of susceptibility of Candida albicans and Candida glabrata to miconazole].
Kurnatowski P; Makieło L; Horwatt-Bozyczko E
Wiad Parazytol; 2001; 47(4):867-73. PubMed ID: 16886440
[TBL] [Abstract][Full Text] [Related]
10. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy.
Shahid Z; Sobel JD
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):354-6. PubMed ID: 19501794
[TBL] [Abstract][Full Text] [Related]
11. Resistance to antifungal agents in the critical care setting: problems and perspectives.
Martins MD; Rex JH
New Horiz; 1996 Aug; 4(3):338-44. PubMed ID: 8856751
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
[TBL] [Abstract][Full Text] [Related]
13. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
14. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
Rautemaa R; Richardson M; Pfaller M; Koukila-Kähkölä P; Perheentupa J; Saxén H
J Antimicrob Chemother; 2007 Oct; 60(4):889-92. PubMed ID: 17704513
[TBL] [Abstract][Full Text] [Related]
15. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
Tortorano AM; Prigitano A; Biraghi E; Viviani MA;
J Antimicrob Chemother; 2005 Oct; 56(4):777-9. PubMed ID: 16144871
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological advances in the treatment of invasive candidiasis.
Deck DH; Guglielmo BJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):137-49. PubMed ID: 16441215
[TBL] [Abstract][Full Text] [Related]
17. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals.
Zaoutis TE; Foraker E; McGowan KL; Mortensen J; Campos J; Walsh TJ; Klein JD
Diagn Microbiol Infect Dis; 2005 Aug; 52(4):295-8. PubMed ID: 15922535
[TBL] [Abstract][Full Text] [Related]
20. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults.
Gualco L; Debbia EA; Bandettini R; Pescetto L; Cavallero A; Ossi MC; Schito AM; Marchese A
Int J Antimicrob Agents; 2007 Feb; 29(2):179-84. PubMed ID: 17175140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
